Mezzion Pharma Co.Ltd Total Liabilities
Mezzion Pharma Co.Ltd total liabilities. Based on the latest financial reports, Mezzion Pharma Co.Ltd (140410) has total liabilities worth ₩86.20 Billion KRW (≈ $58.42 Million USD) as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check Mezzion Pharma Co.Ltd (140410) asset resilience to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Mezzion Pharma Co.Ltd (2012–2025)
Total liabilities of Mezzion Pharma Co.Ltd from 2012 to 2025. This chart illustrates how Mezzion Pharma Co.Ltd's total liabilities have evolved over time, based on quarterly financial data. Explore Mezzion Pharma Co.Ltd long-term investment intensity to see how much of total assets are deployed in long-term investments.
Mezzion Pharma Co.Ltd Competitors by Total Liabilities
The table below lists competitors of Mezzion Pharma Co.Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Shenzhen Tongyi Industry Co Ltd
SHE:300538
|
China | CN¥1.27 Billion |
|
Community Health Systems Inc
NYSE:CYH
|
USA | $13.34 Billion |
|
Chongqing New Dazheng Property Grp
SHE:002968
|
China | CN¥711.44 Million |
|
Izertis Sa
MC:IZER
|
Spain | €178.27 Million |
|
Ring Energy Inc
NYSE MKT:REI
|
USA | $632.74 Million |
|
Panin Financial Tbk
JK:PNLF
|
Indonesia | Rp174.93 Trillion |
|
Clearview Wealth Ltd
AU:CVW
|
Australia | AU$717.27 Million |
|
Nanjing Chixia Development Co Ltd
SHG:600533
|
China | CN¥14.53 Billion |
Liability Composition Analysis (2012–2025)
This chart breaks down Mezzion Pharma Co.Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see 140410 asset base.
Liquidity & Leverage Metrics
Mezzion Pharma Co.Ltd Total Liabilities Ratios Explained
Mezzion Pharma Co.Ltd total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.68 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 2.21 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.69 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Mezzion Pharma Co.Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Mezzion Pharma Co.Ltd (2012–2025)
The table below shows the annual total liabilities of Mezzion Pharma Co.Ltd from 2012 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | ₩80.83 Billion ≈ $54.78 Million |
+189.35% |
| 2024-12-31 | ₩27.94 Billion ≈ $18.93 Million |
-9.02% |
| 2023-12-31 | ₩30.70 Billion ≈ $20.81 Million |
+10.52% |
| 2022-12-31 | ₩27.78 Billion ≈ $18.83 Million |
+31.41% |
| 2021-12-31 | ₩21.14 Billion ≈ $14.33 Million |
+12.36% |
| 2020-12-31 | ₩18.82 Billion ≈ $12.75 Million |
+17.28% |
| 2019-12-31 | ₩16.04 Billion ≈ $10.87 Million |
-9.56% |
| 2018-12-31 | ₩17.74 Billion ≈ $12.02 Million |
-14.99% |
| 2017-12-31 | ₩20.87 Billion ≈ $14.14 Million |
-51.57% |
| 2016-12-31 | ₩43.09 Billion ≈ $29.20 Million |
+6.35% |
| 2015-12-31 | ₩40.52 Billion ≈ $27.46 Million |
+921.54% |
| 2012-12-31 | ₩3.97 Billion ≈ $2.69 Million |
-- |
About Mezzion Pharma Co.Ltd
Mezzion Pharma Co.,Ltd. engages in the development, licensing, and commercialization of drugs for the treatment of vascular diseases. It is developing Udenafil, a PDE5 inhibitor to treat erectile dysfunction, benign prostatic hyperplasia, pulmonary arterial hypertension, overactive bladder, hepatic portal hypertension, and chronic obstructive pulmonary diseases. The company was formerly known as … Read more